Sermorelin vs ipamorelin: what each does, and why they are usually sold together

Sermorelin is the first 29 amino acids of native GHRH, the shortest piece that keeps full activity at the GHRH receptor ^[1]. Ipamorelin is a five-amino-acid synthetic peptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2, built by Novo Nordisk in the 1990s to act on the ghrelin receptor, GHSR-1a ^[2].

Both receptors sit on the somatotroph cells of the anterior pituitary, and both keep somatostatin, the brake on growth hormone, in play. Neither adds growth hormone to the body; each makes the pituitary release its own.

What set ipamorelin apart from the ghrelin-mimicking peptides before it, GHRP-2 and GHRP-6, was selectivity. In the original animal work it released growth hormone without the rise in ACTH and cortisol that the older peptides caused, and without a rise in prolactin ^[2]. Whether that holds the same way in people has not been tested in a dedicated trial.

The two also differ in how long they last. Native GHRH survives for minutes in the blood ^[3], and sermorelin is similarly short-lived. In the one human pharmacokinetic study, ipamorelin had a terminal half-life of about two hours, with the growth hormone peak about 40 minutes after the infusion ^[4].

GHRH and the ghrelin-type peptides amplify each other: given together, they produce a larger growth hormone pulse than either does alone. That has been shown repeatedly in physiology studies of healthy adults ^[5]. It is the basis for the "GHRH plus GHRP" blends sold by telehealth clinics, which usually pair ipamorelin with CJC-1295 rather than with sermorelin, though sermorelin-ipamorelin blends are sold as well.

A bigger pulse on a hormone test is not the same thing as a benefit. No trial has measured what such a combination does to body composition, recovery, sleep or ageing in healthy adults over months.

Sermorelin. Its approval, as Geref, was for children with idiopathic growth hormone deficiency ^[6]. In adults the evidence is small and short. The most cited study gave GHRH(1-29) to 10 older men for 14 days and brought their growth hormone and IGF-1 toward the levels of 9 young men ^[7]. The longest controlled study used a close analogue in 19 adults aged 55 to 71 for 16 weeks, and measured hormone levels ^[8]. There is no Phase 3 trial in adults.

Ipamorelin. The human record is two things. A 1999 dose-escalation study in healthy men, eight per dose group, given by intravenous infusion, which set out its basic pharmacology ^[4]. And a clinical development programme for something else entirely: ileus, the stalled bowel after abdominal surgery. In the published Phase 2 trial, 117 patients after bowel resection received intravenous ipamorelin or placebo twice daily; the median time to a tolerated meal was 25.3 hours against 32.6, a difference that was not statistically significant (p = 0.15) ^[9]. A second, larger Phase 2 trial of 320 patients was completed in May 2014, and no results have been posted on ClinicalTrials.gov ^[10]. No later trial is registered. Ipamorelin has never been approved in the United States, and we found no authorised product in the European, UK, Australian or Canadian regulators' databases ^[11].

Neither drug has been studied for the purposes clinics advertise it for. Sermorelin at least has an approval history and a safety record in children. Ipamorelin has a few hundred hospital patients treated for a week.

This is where they part ways most sharply.

Sermorelin's maker stopped selling Geref in 2008, and FDA withdrew the approvals in 2009 ^[12]. In 2013 FDA determined that the withdrawal was not for safety or effectiveness reasons ^[13], which keeps sermorelin eligible for patient-specific compounding under section 503A. A licensed pharmacy may prepare it against an individual prescription.

Ipamorelin has no such route. Its nomination for the 503A bulks list was withdrawn in September 2024, after FDA had placed it in Category 2 of its interim policy, the category for substances that raise significant safety concerns ^[14]. The Pharmacy Compounding Advisory Committee discussed it in October 2024, and it has not been added to the 503A list since. Under the separate 503B policy for outsourcing facilities, it is still in Category 2 ^[15]. In plain terms, there is no list under which a compounding pharmacy may lawfully use ipamorelin for a human patient, although clinics sell it. Our regulatory tracker follows the changes.

Sermorelin's safety data comes mainly from its use in children, where it was generally well tolerated ^[6]; there is no long-term record in adults. Ipamorelin's comes from the ileus trials, where adverse events were as common on placebo as on the drug (87.5% against 94.8%) in a population recovering from surgery ^[9], which says little about healthy adults.

The shared cautions are those of anything that raises growth hormone and IGF-1: not with active cancer, care with diabetes or impaired glucose tolerance, and a prescriber who checks IGF-1. Both need a working pituitary; if the gland is damaged, neither is the right tool.

On evidence, neither wins: both have short, small human records for the uses they are sold for. On mechanism, they are complementary, which is why combinations exist, and a combination is two unproven drugs rather than one. On legal status the difference is clear. Sermorelin can be prescribed and compounded inside the rules. Ipamorelin cannot, whatever the clinic's page says.

If you are considering either, the questions worth putting to the prescriber are which pharmacy makes it, under which provision, and how IGF-1 will be checked. The related comparisons are sermorelin vs tesamorelin, two GHRH-type peptides with very different evidence, and tesamorelin vs ipamorelin.

This page is informational and is not medical advice. It compares published evidence and regulatory status; it cannot tell you whether either peptide is appropriate for you. Both raise growth hormone and IGF-1 and are unsuitable for people with active cancer. Whether to start, what to use and how to monitor it are decisions for a licensed prescriber who knows your medical history. Last reviewed October 2026.